Camurus Navigation
  • About Camurus
    • CEO statement
    • Management team
    • Board of directors
    • Career
    • Code of conduct
  • Products
  • Pipeline
  • Technologies
    • FluidCrystal® injection depot
    • FluidCrystal® topical bioadhesive
    • FluidCrystal® nanoparticles
  • Investors
    • The share
    • Shareholders
    • Analyst Coverage
    • General meetings
    • Corporate governance
    • Press releases
    • Events & presentations
    • Financial reports
    • Subscription
    • IR contact
    • Prospectus
  • Media
  • Contact
  • English
    • Swedish
    • German
  • About Camurus
    • CEO statement
    • Management team
    • Board of directors
    • Career
    • Code of conduct
  • Products
  • Pipeline
  • Technologies
    • FluidCrystal® injection depot
    • FluidCrystal® topical bioadhesive
    • FluidCrystal® nanoparticles
  • Investors
    • The share
    • Shareholders
    • Analyst Coverage
    • General meetings
    • Corporate governance
    • Press releases
    • Events & presentations
    • Financial reports
    • Subscription
    • IR contact
    • Prospectus
  • Media
  • Contact
  • English
    • Swedish
    • German

CAM2038 opioid dependence

products/#cam2038opiod
  • About Camurus
  • Presentations
  • Pipeline
  • Products
  • Technologies
  • Investors
  • Career
  • Legal notice
  • Privacy
  • Contact
  • IR contact

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close